Compare NUVL & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | DUOL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.4B |
| IPO Year | 2021 | 2021 |
| Metric | NUVL | DUOL |
|---|---|---|
| Price | $105.83 | $148.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | $135.00 | ★ $281.00 |
| AVG Volume (30 Days) | 548.0K | ★ 1.7M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 338.81 |
| EPS | N/A | ★ 8.04 |
| Revenue | N/A | ★ $964,271,000.00 |
| Revenue This Year | N/A | $40.50 |
| Revenue Next Year | N/A | $22.55 |
| P/E Ratio | ★ N/A | $18.69 |
| Revenue Growth | N/A | ★ 39.86 |
| 52 Week Low | $55.54 | $147.70 |
| 52 Week High | $112.88 | $544.93 |
| Indicator | NUVL | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 27.23 |
| Support Level | $97.43 | $169.63 |
| Resistance Level | $108.65 | $179.01 |
| Average True Range (ATR) | 4.95 | 7.56 |
| MACD | 0.48 | -1.88 |
| Stochastic Oscillator | 82.96 | 1.77 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.